ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204
- 43
NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204.
Axonal loss is a common, yet unaddressed pathology, in a broad range of chronic and acute diseases of the central and ocular nervous systems. AXER-204 is the first in a new class of therapy designed to remove inhibitory proteins from the CNS environment allowing for axonal regrowth and increased plasticity. These changes harness the body’s ability to regenerate new neural connections through rewiring. “Given the promising results seen in preclinical studies, it is our hope that AXER-204 will become the first therapeutic shown to restore function and reverse damage in spinal cord injury and other CNS diseases,” says ReNetX President and CSO George Maynard, PhD.
The Phase 1 open-label, dose escalation “RESET” trial will evaluate the safety, tolerability, and pharmacokinetics of AXER-204 in patients with chronic spinal cord injury and is expected to enroll approximately 24 patients. An estimated 300,000 people are currently living with chronic spinal cord injury in the U.S., and there is currently no approved therapeutic to restore sensory or motor function after injury. The company was founded by Stephen Strittmatter, MD, PhD, Vincent Coates Professor of Neurology at Yale University.
About the Phase 1 RESET Study: For more information, please visit ClinicalTrials.gov.
About ReNetX Bio, Inc.: For more information, please visit www.renetx.com.
CONTACT: [email protected]
GlobeNewswire è una delle più grandi reti di distribuzione di newswire al mondo, specializzata nella distribuzione di comunicati stampa aziendali, informazioni finanziarie e contenuti multimediali a media, investitori e lettori di tutto il mondo.
- ACE Money Transfer annuncia la sua attesissima campagna Salam Bangladesh con premi più cospicui per il Ramadan
- Vent'anni dopo l'IPO, il valore di mercato di Weichai Power aumenta di 30 volte, distribuendo dividendi per 28 miliardi di RMB
- ChainUp rafforza la posizione di sicurezza con l'acquisizione della certificazione SOC 2 Type 2
- Bybit espande gli orizzonti del trading con le opzioni Solana
- Invibes Advertising : Forte crescita dei risultati annuali 2023.
- EQS-News: Dopo un 2023 estremamente positivo, con 1,7 miliardi di euro di nuovi capitali raccolti, Golding nomina Richard Wilmes, Head of Secondaries, nuovo partner